ESC 365 - Understanding epigenetics - The potential rationale for BET inhibition in management of cardiovascular disease.

ESC Premium Access

Understanding epigenetics - The potential rationale for BET inhibition in management of cardiovascular disease.

Session: LDL-c: done deal, next epigenetics? (EBAC Accredited)

Topic: Secondary Prevention

Speaker: Doctor J. Plutzky (Boston, US)

Organised by PACE-CME, Physicians' Academy for Cardiovascular Education, supported with an educational grant from Resverlogix

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Doctor Jorge Plutzky

Brigham and Women's Hospital, Boston (United States of America)

5 presentations

0 follower

4 more presentations in this session

Introduction - LDL-c: done deal, next epigenetics?

Speaker: Professor U. Laufs (Leipzig, DE)

The real residual risk in patients with cardiovascular disease and diabetes: the promise of epigenetics.

Speaker: Professor E. Stroes (Amsterdam, NL)

A clinical view on BET inhibition in targeting residual risk in cardiovascular disease and diabetes.

Speaker: Professor K. Ray (London, GB)

Discussion and summary - LDL-c: done deal, next epigenetics? .

Speaker: Professor U. Laufs (Leipzig, DE)

Access the full session

LDL-c: done deal, next epigenetics? (EBAC Accredited)

Speakers: Doctor J. Plutzky, Professor U. Laufs, Professor E. Stroes, Professor K. Ray, Professor U. Laufs

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources